Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
231
Employees231
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
231
Employees231

CAPR Key Statistics

Market cap
552.03M
Market cap552.03M
Price-Earnings ratio
-3.79
Price-Earnings ratio-3.79
Dividend yield
Dividend yield
Average volume
9.54M
Average volume9.54M
High today
$9.81
High today$9.81
Low today
$9.22
Low today$9.22
Open price
$9.40
Open price$9.40
Volume
1.38M
Volume1.38M
52 Week high
$40.37
52 Week high$40.37
52 Week low
$2.96
52 Week low$2.96

Stock Snapshot

With a market cap of 552.03M, Capricor(CAPR) trades at $9.50. The stock has a price-to-earnings ratio of -3.79.

On 2026-09-04, Capricor(CAPR) stock traded between a low of $9.22 and a high of $9.81. Shares are currently priced at $9.50, which is +3.0% above the low and -3.2% below the high.

The Capricor(CAPR)'s current trading volume is 1.38M, compared to an average daily volume of 9.54M.

In the last year, Capricor(CAPR) shares hit a 52-week high of $40.37 and a 52-week low of $2.96.

In the last year, Capricor(CAPR) shares hit a 52-week high of $40.37 and a 52-week low of $2.96.

CAPR News

Barchart 2d
Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. - Lead Plaintiff Deadline is September 28, 2026 - Barchart.com

...

Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. - Lead Plaintiff Deadline is September 28, 2026 - Barchart.com
TipRanks 3d
Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (CAPR) to Overweight from Neutral with a price target of $25, up from $2. The FDA last week...

Analyst ratings

70%

of 10 ratings
Buy
30%
Hold
70%
Sell
0%

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.